WEST Search History

DATE: Wednesday, May 14, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,JP	AB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR	}	
L2	Liposome\$ adj2 adsorb\$	76	L2
L1	transferosomes	11	L1

END OF SEARCH HISTORY

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 11 of 11 returned.

☐ 1. Document ID: US 6372249 B1

L1: Entry 1 of 11

File: USPT

Apr 16, 2002

US-PAT-NO: 6372249

DOCUMENT-IDENTIFIER: US 6372249 B1

** See image for Certificate of Correction **

TITLE: Senscent cell-derived inhibitors of DNA synthesis

DATE-ISSUED: April 16, 2002

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Smith; James R. Houston TX
Drutz; David J. Houston TX
Wilson; Deborah R. Houston TX
Zumstein; Louis A. Houston TX

US-CL-CURRENT: 424/450; 514/12, 514/2, 530/350

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw, Description

2. Document ID: US 6315756 B1

L1: Entry 2 of 11

File: USPT

Nov 13, 2001

US-PAT-NO: 6315756

DOCUMENT-IDENTIFIER: US 6315756 B1

TITLE: Tumescent solution

DATE-ISSUED: November 13, 2001

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Tankovich; Nikolai San Diego CA 92129

US-CL-CURRENT: 604/35; 514/672, 514/759

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw, Desc Image

☐ 3. Document ID: US 6302863 B1

L1: Entry 3 of 11

File: USPT

Oct 16, 2001

US-PAT-NO: 6302863

DOCUMENT-IDENTIFIER: US 6302863 B1

TITLE: Method for removal of lipids via a perfluorocarbon tumescent solution

DATE-ISSUED: October 16, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Tankovich; Nikolai

San Diego

CA

92129

US-CL-CURRENT: 604/35; 128/898

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw Desc Image

4. Document ID: US 6022560 A

L1: Entry 4 of 11

File: USPT

Feb 8, 2000

US-PAT-NO: 6022560

DOCUMENT-IDENTIFIER: US 6022560 A

TITLE: Pharmaceutical compositions, novel uses, and novel form of

.alpha.-tocopherylphosphocholine

DATE-ISSUED: February 8, 2000

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Yazdi; Parvin T.

Madison

WI

Pruss; Thaddeus P.

Madison

WI

US-CL-CURRENT: $\underline{424}/\underline{450}$; $\underline{424}/\underline{43}$, $\underline{424}/\underline{451}$, $\underline{424}/\underline{464}$, $\underline{514}/\underline{458}$, $\underline{514}/\underline{78}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw. Desc Image

☐ 5. Document ID: US 5980898 A

L1: Entry 5 of 11

File: USPT

Nov 9, 1999

US-PAT-NO: 5980898

DOCUMENT-IDENTIFIER: US 5980898 A

TITLE: Adjuvant for transcutaneous immunization

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME

CITY

STATE 2

ZIP CODE

COUNTRY

Glenn; Gregory M.

Bethesda

MD

Alving; Carl R.

Bethesda

MD

US-CL-CURRENT: 424/184.1; 424/240.1, 424/241.1, 424/275.1, 424/449, 424/450, 424/85.1, 530/363, 530/403

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc Image

KWIC

☐ 6. Document ID: US 5910306 A

L1: Entry 6 of 11

File: USPT

Jun 8, 1999

US-PAT-NO: 5910306

DOCUMENT-IDENTIFIER: US 5910306 A

TITLE: Transdermal delivery system for antigen

DATE-ISSUED: June 8, 1999

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Alving; Carl R.

Bethesda 1

MD

Glenn; Gregory M.

Bethesda MD

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

KWIC

☐ 7. Document ID: US 5763423 A

L1: Entry 7 of 11

File: USPT

Jun 9, 1998

US-PAT-NO: 5763423

DOCUMENT-IDENTIFIER: US 5763423 A

TITLE: Pharmaceutical compositions, novel uses, and novel form of

tocopherylphosphocholine

DATE-ISSUED: June 9, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY ·

Yazdi; Parvin T.

Madison

WI

Pruss; Thaddeus P.

Madison

WI

US-CL-CURRENT: <u>514/78</u>; <u>424/450</u>, <u>514/458</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draws Desc Image

KWC

☐ 8. Document ID: US 5703062 A

L1: Entry 8 of 11

File: USPT

Dec 30, 1997

US-PAT-NO: 5703062

DOCUMENT-IDENTIFIER: US 5703062 A

TITLE: N-het-substituted glycerophosphoethanolamines

DATE-ISSUED: December 30, 1997

INVENTOR - INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Nair; Haridasan K.

Madison

WI

I, halldasan K. Madison W

US-CL-CURRENT: 514/77

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc Image

KMIC

☐ 9. Document ID: US 5665714 A

L1: Entry 9 of 11

File: USPT

STATE

Sep 9, 1997

US-PAT-NO: 5665714

DOCUMENT-IDENTIFIER: US 5665714 A

TITLE: N-substituted glycerophosphoethanolamines

DATE-ISSUED: September 9, 1997

INVENTOR-INFORMATION:

NAME
Paltauf; Friedrich

Paltauf; Friedrich Graz
Hermetter; Albin Graz
Franzmair; Rudolf Linz

nz AT

ZIP CODE

US-CL-CURRENT: 514/94; 548/119

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

CITY

KWIC

COUNTRY

AT

AT

☐ 10. Document ID: WO 200041671 A2

L1: Entry 10 of 11

File: DWPI

Jul 20, 2000

DERWENT-ACC-NO: 2000-505713

DERWENT-WEEK: 200045

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Removal of subcutaneous fat by application of perfluorocarbon to emulsify the fat followed by liposuction, avoids use of instruments and causes minimal damage to blood vessels

INVENTOR: TANKOVICH, N

PRIORITY-DATA: 1999US-0231705 (January 12, 1999)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

WO 200041671 A2

July 20, 2000

E

027

A61K000/00

INT-CL (IPC): A61 K 0/00

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC

☐ 11. Document ID: JP 2002533379 W WO 200038653 A1 AU 9925137 A CZ 200102038 A3 NO 200103164 A EP 1140021 A1 BR 9816113 A CN 1327382 A HU 200104424 A2 KR 2001107991 A US 20020064524 A1

L1: Entry 11 of 11

File: DWPI

Oct 8, 2002

DERWENT-ACC-NO: 2000-490777

DERWENT-WEEK: 200281

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Topical formulations with penetrant adaptability to transport agents through smaller pores, contain consistency builder with antioxidant and microbicide for storage stability

INVENTOR: CEVC, G

PRIORITY-DATA: 1998WO-EP08421 (December 23, 1998)

PATENT-FAMILY:

PUB-NO		PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 20025333	379 W	October 8, 2002		087	A61K009/10
WO 20003865	3 A1	July 6, 2000	E	072	A61K009/127
AU 9925137	A	July 31, 2000		000	A61K009/127
CZ 20010203	8 A3	September 12, 2001		000	A61K009/127
NO 20010316	54 A	August 22, 2001		000	A61K009/127
EP 1140021	A1	October 10, 2001	E	000	A61K009/127
BR 9816113	A .	October 23, 2001		000	A61K009/127
CN 1327382	A	December 19, 2001	•	000	A61K009/127
HU 20010442	4 A2	March 28, 2002		000	A61K009/127
KR 20011079	91 A	December 7, 2001		000	A61K009/127
US 20020064	524 A1	May 30, 2002		000	A61K038/48

INT-CL (IPC): $\underline{A61}$ \underline{K} $\underline{9/10}$; $\underline{A61}$ \underline{K} $\underline{9/127}$; $\underline{A61}$ \underline{K} $\underline{31/56}$; $\underline{A61}$ \underline{K} $\underline{31/715}$; $\underline{A61}$ \underline{K} $\underline{38/48}$; $\underline{A61}$ \underline{K} $\underline{47/02}$; $\underline{A61}$ \underline{K} $\underline{47/10}$; $\underline{A61}$ \underline{K} $\underline{47/12}$; $\underline{A61}$ \underline{K} $\underline{47/14}$; $\underline{A61}$ \underline{K} $\underline{47/18}$; $\underline{A61}$ \underline{K} $\underline{47/20}$; $\underline{A61}$ \underline{K} $\underline{47/22}$; $\underline{A61}$ \underline{K} $\underline{47/24}$; $\underline{A61}$ \underline{K} $\underline{47/26}$; $\underline{A61}$ \underline{K} $\underline{47/28}$; $\underline{A61}$ \underline{K} $\underline{47/32}$; $\underline{A61}$ \underline{F} $\underline{17/06}$; $\underline{A61}$ \underline{P} $\underline{17/06}$; $\underline{A61}$ \underline{P} $\underline{17/14}$; $\underline{A61}$ \underline{P} $\underline{19/00}$; $\underline{A61}$ \underline{P} $\underline{17/00}$; $\underline{A61}$ \underline{P}

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc | Image |

KMC

Generate Collec	tion Print
Terms	Documents
ransferosomes	11

Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection

Print

L2: Entry 63 of 76

File: USPT

Jul 31, 1990

DOCUMENT-IDENTIFIER: US 4944948 A

** See image for Certificate of Correction **
TITLE: EGF/Liposome gel composition and method

Detailed Description Text (28):

The aqueous medium used in forming the composition may contain dissolved EGF, at a suitable concentration The suspension formed in this manner includes encapsulated, liposome-adsorbed, and free EGF. Free EGF can be removed, if desired, by conventional methods, such as molecular sieve filtration or the like.

Detailed Description Text (29):

Alternatively, free EGF may be added to preformed liposomes at a suitable concentration, producing a suspension with liposome-adsorbed and free EGF. According to one aspect of the invention, it has been found that the in vivo release kinetics of EGF from EGF/liposomes containing absorbed EGF only is comparable for EGF/liposomes prepared to include both adsorbed and encapsulated EGF (Example 5).

<u>Detailed Description Text</u> (59):

The EGF available in the donor compartment from various EGF/liposome compositions were similarly measured. FIG. 7-9 shows plots of EGF available in the donor compartment, as a function of time, from (Composition I) EPC/EPG liposomes with encapsulated EGF (FIG. 7), (Compositions II) EPC/EPG/cholesterol liposomes with encapsulated EGF (FIG. 8), and (Composition III) EPC/EPG/cholesterol with adsorbed EGF. All three compositions contain free EGF, and thus also are expected to contain liposome-adsorbed EGF.

Detailed Description Text (68):

The above results also indicate that <u>liposome-adsorbed</u> EGF in the EGF/liposomes is released from the liposomes in vivo at substantially the same rate as encapsulated EGF. This result confirms that EGF is tightly bound to negatively charged liposomes (containing at least 20 mole percent negatively charged phospholipid), and that an effective EGF/liposome formulation can be made by surface adsorption to liposomes.

Detailed Description Text (122):

FIG. 12 shows similar plots from five Bronaugh cells of the availability of free EGF in the donor cell, as a function of time, for an EGF/liposome composition having the Composition II formulation EPG/EPC/Chol/a-toc (1/1/1/0.03, w/w/w/w). As with the composition above, the liposomes contained liposome-encapsulated EGF, as well as liposome-adsorbed and free EGF.

5/14/03 9:40